Artal Group S.A.
Artal Group S.A. reported 2 US-listed holdings worth $931.1 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Cava Group, Inc. (54.9%) and Lexicon Pharmaceuticals Inc. (45.1%). Against the quarter before, it opened 0 positions, added to 1, trimmed 1 and sold out of 0.
The 2 largest of its 2 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned -19.4% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Added to 1
- Lexicon Pharmaceuticals Inc. LXRX+20.4 million shares · +13%
Trimmed 1
- Cava Group, Inc. CAVA-3.0 million shares · -32%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Cava Group, Inc. CAVA | 6.5M | $510.7 million | 54.85% | -3.0M |
| Lexicon Pharmaceuticals Inc. LXRX | 175.2M | $420.4 million | 45.15% | +20.4M |